Oceana Therapeutics Inc

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

24 documents for Oceana Therapeutics Inc

- Solesta(R)
ST. LOUIS, Oct. 13, 2011 /PRNewswire/ -- CuraScript, Inc., a wholly owned subsidiary of Express Scripts, Inc., is now the exclusive specialty pharmacy for patients using , a product of Oceana Therapeutics Inc., under an agreement announced today. Part of Express Scripts HealthBridge Pharma & Biotech services, CuraScript SD Specialty Distribution will be one of two national distributors responsible for delivering Solesta to healthcare providers. Solesta is the only nonsurgical treatment approved by the Food and Drug Administration for patients who fail conservative therapy for fecal (bowel) incontinence. A biocompatible tissue-bulking agent, Solesta is an injectable gel administered in an outpatient setting without the need for anesthesia. Oceana Therapeutics has exclusive righ...
- U.S. Newswire
- October 13, 2011
- 'A Buyer's Market' for N.J.'S Small Biotechs
The ability of a drug to get reimbursements for users from insurance companies is one of the biggest determinants in its valuation, [David Tierney] said. Among those in demand are drugs that treat chronic ailments like diabetes, [Tracy Warren] said - "drugs you may take for the rest of your life, as opposed to acute therapies, like for pain or a surgery," she added. "You want a drug that you can sell daily. Nanette W. Mantell, partner at the law firm of Reed Smith LLP in Princeton and vice chair of its global life sciences health care industry group, said, Despite making cutbacks, pharmaceutical companies are still very cash-rich entities. Broadly speaking, big pharma companies and investors will be attracted to those biotechnology firms that have drugs that serve "unmet medical needs...

..., president and chief operating officer of Oceana Therapeutics Inc., of Edison. Tierney said Oceana ...
- NJBIZ
- September 08, 2009
- Medical Devices:
...P100014 FDA-2011-M-0445.... Oceana Therapeutics,. Solesta injectable gel..... May 27,...
- FR, August 04, 2011
- Notices
- Food and Drug Administration

- Salix Pharmaceuticals to Acquire Oceana Therapeutics.
SOLESTA([R]) and DEFLUX ([R]) Expand Salix's Product Portfolio RALEIGH, N.C. -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Oceana Therapeutics, L...
- Business Wire
- November 08, 2011
- Concentric Pharma Advertising Tapped to Advertise SOLESTA[TM] Upon Approval.
... to Design Online and Offline Campaigns for Oceana's Fecal Incontinence Device . NEW YORK -- Headline... device SOLESTA[TM] from Oceana Therapeutics, Inc. SOLESTA[TM] is currently under review by the...
- Business Wire
- September 13, 2010
- Concentric
partner and COO Ken Begasse, Jr. describes 2008 as "pivotal." The agency opened a London office, grew senior leadership and moved New York City headquarters to a new space. It successfully faced a multitude of challenges, including stalled launches, suspended budgets and mergers, and continued a five-year roll of double-digit growth, ending the year up 20% to $11.5 million. The US crew moved into a new, custom-designed 17,000-plus square-foot space in downtown Manhattan last September. London headcount has grown rapidly to 13, while headcount in New York is down about 10 to 52. Begasse explains that the agency "did some right sizing" at the beginning of this year mostly as a result of client spending freezes. He adds that he's currently looking to hire two people, as client c...

...'s wins include Salix Pharmaceuticals and Oceana Therapeutics - both of which Begasse calls "very p...
- Medical Marketing and Media
- October 09, 2009
- Oceana Therapeutics Announces Definitive Agreement to be Acquired by Salix Pharmaceuticals.
EDISON, N.J. -- Oceana Therapeutics LLC, a privately owned global company focused on commercializing best-in-class specialty therapeutics, today annou...
- Business Wire
- November 08, 2011
- Fda Approves Injectable Gel to Treat Fecal Incontinence
SILVER SPRING, Md., May 27, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a sterile, injectable gel to treat fecal incontinence in patients for whom other therapies such as diet change, fiber therapy or anti-motility medications failed. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

...Solesta is manufactured by Oceana Therapeutics Inc. of Edison, N.J. For more informa...
- U.S. Newswire
- May 27, 2011
- Meetings:
... (PMA) for SOLESTA, sponsored by Oceana. Therapeutics, Inc. SOLESTA is indicated for the t...
- FR, September 23, 2010
- Notices
- Food and Drug Administration
- Urigen Files Request for FDA Meeting.
... clinical program and mutually agreed with Oceana Therapeutics, Inc. to terminate their Consulting A...
- Business Wire
- April 23, 2010